Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1

Obiettivo

Immune Checkpoint Inhibitors (ICPIs) have recently revolutionized the treatment and management of cancer. Yet, progress recorded and impact on long-term survival affect only a limited fraction of patients, as most of the cancer patients do not or incompletely respond to ICPIs due to primary or secondary resistance to these treatments.
NETRIS Pharma is an innovative biotech company based in Lyon. The company has developed NP137, a humanized monoclonal antibody targeting NETRIN-1, able to drive tumor growth inhibition and alleviate resistance to ICPIs, both impacts already confirmed in preclinical models.
The objective of the IMMUNONET project is to conduct a proof-of-efficacy clinical trial assessing the efficacy of NP137 to alleviate suspected resistance to ICPIs. The increased response rate to ICPIs with NP137 would have a major impact on patients having limited treatment options beyond immunotherapies and create significant growth opportunities for NETRIS.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2021-ACCELERATOROPEN-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

NETRIS PHARMA SAS
Contributo netto dell'UE
€ 2 500 000,00
Indirizzo
RUE LAENNEC 28 BATIMENT CHENEY C CENTRE LEON BERARD
69008 Lyon
Francia
PMI
Sì
Regione
Auvergne-Rhône-Alpes Rhône-Alpes Rhône
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 8 327 233,75